Ameriprise
BEAM icon

Ameriprise’s Beam Therapeutics BEAM Stock Holding History

Ameriprise’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-88,732
Closed -$2.15M – 4088
2025
Q3 		$2.15M Buy
+88,732
New +$1.77M ﹤0.01% 2968
2024
Q3 		– Sell
-230,172
Closed -$5.39M – 3933
2024
Q2 		$5.39M Buy
230,172
+1,267
+0.6% +$31.1K ﹤0.01% 2246
2024
Q1 		$7.56M Sell
228,905
-37,090
-14% -$1.16M ﹤0.01% 2037
2023
Q4 		$7.24M Buy
265,995
+249,865
+1,549% +$6.21M ﹤0.01% 2060
2023
Q3 		$388K Buy
16,130
+6,657
+70% +$178K ﹤0.01% 3498
2023
Q2 		$302K Buy
+9,473
New +$307K ﹤0.01% 3604
2023
Q1 		– Sell
-7,337
Closed -$287K – 3940
2022
Q4 		$287K Sell
7,337
-49,291
-87% -$2.21M ﹤0.01% 3600
2022
Q3 		$2.7M Buy
+56,628
New +$3.23M ﹤0.01% 2639
2022
Q2 		– Sell
-9,732
Closed -$558K – 3897
2022
Q1 		$558K Buy
9,732
+7,217
+287% +$473K ﹤0.01% 3444
2021
Q4 		$200K Buy
+2,515
New +$215K ﹤0.01% 3788

Other funds holding BEAM

AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Ameriprise's BEAM Position: Q4 2025 in Review

Ameriprise sold out of Beam Therapeutics (BEAM) in Q4 2025, closing a stake of 88,732 shares — an estimated $2.15M sold.

Ameriprise first reported a position in BEAM in Q4 2021 and held it in 10 quarters. The position peaked at $7.56M in Q1 2024. 246 funds tracked by Wall St. Rank hold BEAM as of Q4 2025.

  • Ameriprise reported no remaining Beam Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Ameriprise sold 88,732 Beam Therapeutics shares in Q4 2025, an estimated $2.15M.
  • Ameriprise first reported a position in Beam Therapeutics in Q4 2021 and held it in 10 quarters.
  • Ameriprise's Beam Therapeutics position peaked at $7.56M in Q1 2024.
  • 246 funds tracked by Wall St. Rank held Beam Therapeutics as of Q4 2025.

Based on Ameriprise's 13F filing for Q4 2025, filed 17 Feb 2026.